| SCTB41 Plus SCTB39G With or Without Standard Therapy in Advanced Solid Tumors (NCT07665970) | Sinocelltech Ltd. | 2026-06-30 |
| A Study to Evaluate the Safety and Efficacy of SCTB35 in Combination With Lenalidomide in Patients With Relapsed or Refractory Follicular Lymphoma (NCT07562022) | Sinocelltech Ltd. | 2026-06-09 |
| A Study to Evaluate the Safety and Efficacy of SCTB35 in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (NCT07570823) | Sinocelltech Ltd. | 2026-06-04 |
| Phase I/II Study of SCTB41 Plus SCTB39-1with or Without Standard Therapy in Advanced Solid Tumours (NCT07594028) | Sinocelltech Ltd. | 2026-05-30 |
| SCTB41 Combined With Chemotherapy in Advanced Squamous Non-Small Cell Lung Cancer (NCT07662395) | Sinocelltech Ltd. | 2026-05-09 |
| A Clinical Study of SCTB41 Combined With Docetaxel in Patients With Previously Treated Locally Advanced or Metastatic Non-Small Cell Lung Cancer（Phase II Study Ongoing） (NCT07609251) | Sinocelltech Ltd. | 2026-05-01 |
| A Study to Evaluate the Safety and Efficacy of SCTC21C in Combination With Bortezomib, Cyclophosphamide, and Dexamethasone in Patients With Newly Diagnosed Systemic Light-Chain Amyloidosis (NDSLCA) (NCT07388602) | Sinocelltech Ltd. | 2026-01-08 |
| A Study to Evaluate the Safety and Tolerability of SCTB14 as First-Line Therapy in Non-Small Cell Lung Cancer. (NCT07362459) | Sinocelltech Ltd. | 2025-12-30 |
| A Study to Evaluate the Safety and Efficacy of SCTC21C in Combination With Bortezomib, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant (NCT07297329) | Sinocelltech Ltd. | 2025-12-29 |
| Efficacy and Safety of SCT650C in Participants With Moderate to Severe Hidradenitis Suppurativa (NCT07244510) | Sinocelltech Ltd. | 2025-12-16 |
| Phase I/II Study of SCTB39G in Advanced Solid Tumours (NCT07077252) | Sinocelltech Ltd. | 2025-07-28 |
| Phase I/II Study of SCTB39-1 in Advanced Solid Tumours (NCT07050641) | Sinocelltech Ltd. | 2025-06-23 |
| A Study of SCTT11 in Healthy Participants and Participants with Thyroid Eye Disease. (NCT06769984) | Sinocelltech Ltd. | 2025-02-19 |
| A Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Recombinant Herpes Zoster Vaccine (NCT06801509) | Sinocelltech Ltd. | 2025-02-15 |
| A Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Recombinant Respiratory Syncytial Virus Vaccine (NCT06754605) | Sinocelltech Ltd. | 2025-02-06 |
| A Study of SCTB35 in Patients with Systemic Lupus Erythematosus (NCT06841042) | Sinocelltech Ltd. | 2025-02-01 |
| A Clinical Study of SCTC21C in Participants With Plasma Cell-driven Autoimmune Diseases (NCT06774664) | Sinocelltech Ltd. | 2025-01-01 |
| Multicenter, Phase I/II Study to Evaluate the Safety, Tolerability, PK and Efficacy of SCT520FF in Patients With nAMD (NCT06672536) | Sinocelltech Ltd. | 2024-11-26 |
| Aims to Explore the Safety, Tolerability, and Preliminary Efficacy of SCTB41 in Adult Patients with Advanced Malignant Solid Tumours. (NCT06600022) | Sinocelltech Ltd. | 2024-10-10 |
| Efficacy and Safety of SCT650C in Participants With Axial Spondyloarthritis (NCT06197009) | Sinocelltech Ltd. | 2024-07-01 |
| Aims to Explore the Safety, Tolerability, and Preliminary Efficacy of SCTB14 in Adult Patients With Advanced Malignant Solid Tumours. (NCT06304818) | Sinocelltech Ltd. | 2024-04-30 |
| Efficacy and Safety Evaluation Study of SCT800 in Previously Untreated Hemophilia A Patients. (NCT07437404) | Sinocelltech Ltd. | 2024-04-26 |
| A First-in-human Study of SCTB35 in Patients With Relapse/Refractory B-cell Non-Hodgkin Lymphoma (NCT06318884) | Sinocelltech Ltd. | 2024-04-01 |
| A Clinical Study of SCTC21C in Participants With CD38+ Hematologic Malignancies (NCT06252298) | Sinocelltech Ltd. | 2024-02-28 |
| A Study to Evaluate the Efficacy, Safety, and Immunogenicity of SCT1000 in Healthy Women Aged 18-45 Years (NCT06041061) | Sinocelltech Ltd. | 2023-08-13 |
| A Study to Evaluate the Immunogenicity and Safety of A Recombinant Protein COVID-19 Vaccine as Booster Vaccines (NCT05933512) | Sinocelltech Ltd. | 2023-08-10 |
| Evaluate the Safety and Tolerability of SCT650C in Healthy Volunteers (NCT05894707) | Sinocelltech Ltd. | 2023-06-01 |
| This Study Will Compare the Efficacy and Safety of SCT510A Administered by Intravitreal Injection (IVT) With Ranibizumab in Patients With wAMD (NCT05480293) | Sinocelltech Ltd. | 2023-02-14 |
| A Phase III Clinical Trial to Evaluate the Efficacy and Safety of SCTV01E in Healthy People (NCT05683561) | Sinocelltech Ltd. | 2023-01-25 |
| A PhaseⅡ Study to Evaluate the Safety & Immunogenicity of SARS-CoV-2 Alpha/Beta/Delta/Omicron Variants COVID-19 Vaccine (NCT05652543) | Sinocelltech Ltd. | 2023-01-05 |
| A Study to Evaluate the Efficacy and Safety of SCTV01E (a COVID-19 Vaccine) in Population Aged ≥18 Years (NCT05308576) | Sinocelltech Ltd. | 2022-12-26 |
| A Study to Evaluate the Immunogenicity and Safety of a Recombinant Protein COVID-19 Vaccine SCTV01E-1 in Population Aged Above 18 Years (NCT05522829) | Sinocelltech Ltd. | 2022-10-15 |
| A Study to Evaluate the Immunogenicity and Safety of a Recombinant Protein COVID-19 Vaccine as a Booster Dose in Population Aged 12-17 Years (NCT05345873) | Sinocelltech Ltd. | 2022-07-01 |
| SCT200 in Combination With SCT-I10A/Paclitaxel/Docetaxel in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (NCT05552807) | Sinocelltech Ltd. | 2022-06-15 |
| A Study to Evaluate the Immunogenicity and Safety of Two Recombinant Protein COVID-19 Vaccines in Population Aged ≥18 Years as Booster Vaccines (NCT05323461) | Sinocelltech Ltd. | 2022-05-30 |
| A Study of the Immunogenicity and Safety of SCTV01C in Population Aged ≥12 Years and Previously Vaccinated With Inactivated COVID-19 Vaccine (NCT05239975) | Sinocelltech Ltd. | 2022-04-25 |
| A Study to Evaluate the Immunogenicity and Safety of SCTV01C and SCTV01E (Two Recombinant Protein COVID-19 Vaccines) in Population Aged ≥12 Years (NCT05308602) | Sinocelltech Ltd. | 2022-04-01 |
| A Phase II Clinical Trial to Evaluate the Immunogenicity and Safety of SCTV01C and SCTV01E in Population Aged ≥12 Years Previously Fully Vaccinated With Inactivated COVID-19 Vaccine (NCT05239806) | Sinocelltech Ltd. | 2022-04-01 |
| A Phase II Clinical Trial to Evaluate the Immunogenicity and Safety of SCTV01E in Population Aged ≥18 Years Previously Fully Vaccinated With mRNA COVID-19 Vaccine (NCT05238441) | Sinocelltech Ltd. | 2022-03-20 |
| A Phase II Clinical Trial to Evaluate the Immunogenicity and Safety of SCTV01C in Population Aged ≥18 Years and Previously Fully Vaccinated With COVID-19 Vaccine (NCT05238454) | Sinocelltech Ltd. | 2022-03-20 |
| A Study to Evaluate Efficacy and Safety of the Combination of SCTA01 & SCTA01C in Outpatients With COVID-19 (NCT05156645) | Sinocelltech Ltd. | 2022-01-15 |
| The Safety and Immunogenicity of SCTV01C in Healthy Population Aged ≥18 Years Previously Vaccinated With mRNA COVID-19 Vaccine. (NCT05043311) | Sinocelltech Ltd. | 2021-12-22 |
| The Safety and Immunogenicity of SCTV01C in Healthy Population Aged ≥18 Years Previously Vaccinated With Inactivated COVID-19 Vaccine. (NCT05043285) | Sinocelltech Ltd. | 2021-12-22 |
| The Safety, Tolerability and Immunogenicity of COVID-19 Vaccine (SCTV01C) in Healthy, Unvaccinated Adults (NCT05148091) | Sinocelltech Ltd. | 2021-12-01 |
| A Phase II Study of SCT1000 in Healthy Women Aged 18 to 45 Years (NCT05060484) | Sinocelltech Ltd. | 2021-10-19 |
| To Evaluate SCTA01 Treatment of High-risk Outpatients With COVID-19 (NCT04709328) | Sinocelltech Ltd. | 2021-03-28 |
| The Efficacy and Safety of SCTA01 in Hospitalized Patients With Severe COVID-19 (NCT04644185) | Sinocelltech Ltd. | 2021-03-27 |
| The Safety and Efficacy of SCTA01 Against COVID-19 in Patients Admitted to High Dependence or Intensive Care (NCT04683328) | Sinocelltech Ltd. | 2021-02-25 |
| SCT-I10A Plus SCT510 Versus Sorafenib as First-Line Therapy for Advanced Hepatocellular Carcinoma (NCT04560894) | Sinocelltech Ltd. | 2020-11-11 |
| Safety, Tolerability and Pharmacokinetics of SCTA01, an Anti-SARS-CoV-2 Monoclonal Antibody, in Healthy Chinese Subjects (NCT04483375) | Sinocelltech Ltd. | 2020-07-24 |
| Study of SCT-I10A Combined SCT200 or SCT-I10A Combined SCT200 Plus Chemotherapy in ESCC and CRC (NCT04229537) | Sinocelltech Ltd. | 2020-03-01 |
| SCT-I10A Plus Standard Chemotherapy in First-line Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma (NCT04146402) | Sinocelltech Ltd. | 2019-12-31 |
| Safety,Efficacy and Pharmacokinetics Evaluation of SCT800 in Previously Treated Paediatric Patients With Severe Haemophilia A. (NCT03947320) | Sinocelltech Ltd. | 2019-12-20 |
| Safety and Efficacy of SCT-I10A in Head and Neck Squamous Cell Carcinoma (NCT04146181) | Sinocelltech Ltd. | 2019-10-31 |
| SCT-I10A or Placebo Plus Docetaxel With Previously Treated Squamous Cell Non-small Cell Lung Cancer (NCT04171284) | Sinocelltech Ltd. | 2019-10-22 |
| Safety and Efficacy of Long-term Treatment With SCT800 in Previously Treated Hemophilia A Patients. (NCT03947567) | Sinocelltech Ltd. | 2019-07-26 |
| Pharmacokinetics and Safety in Healthy Volunteers (NCT03917628) | Sinocelltech Ltd. | 2019-05-29 |
| SCT200 Plus Platinum-based Chemotherapy in Head and Neck Squamous Cell Carcinoma (NCT03874741) | Sinocelltech Ltd. | 2019-05-21 |
| Efficacy and Safety of SCT200 in Patients With Advanced Squamous Non-small Cell Lung Cancer (NCT03808701) | Sinocelltech Ltd. | 2019-03-01 |
| To Evaluate the Efficacy and Safety of SCT510 in the Treatment of Non-small Cell Lung Cancer (NCT03792074) | Sinocelltech Ltd. | 2019-02-01 |
| Evaluation of SCT800 in Prophylaxis Therapy on Previous Treated Patients With Severe Hemophilia A (NCT03815318) | Sinocelltech Ltd. | 2019-01-21 |
| Safety, Tolerability, Pharmacokinetics and Efficacy of SCT-I10A in Patients With Advanced Solid Tumors or Lymphoma (NCT03821363) | Sinocelltech Ltd. | 2018-12-13 |
| Safety and Efficacy of SCT200 in Head and Neck Squamous Cell Carcinoma (NCT03713372) | Sinocelltech Ltd. | 2018-11-28 |
| Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of SCT200 in Patients With Advanced Solid Tumors (NCT03692520) | Sinocelltech Ltd. | 2018-09-30 |
| Safety and Efficacy of SCT200 in Patients With Relapsed or Metastatic Triple Receptor Negative Breast Cancer (NCT03692689) | Sinocelltech Ltd. | 2018-07-20 |
| Safety and Efficacy of SCT200 in Patients With Advanced Esophageal Squamous Cell Carcinoma (NCT03817567) | Sinocelltech Ltd. | 2018-07-17 |
| Safety and Efficacy of Recombinant Anti-EGFR Monoclonal Antibody in Patients With Wild-type RAS and BRAF mCRC (NCT03405272) | Sinocelltech Ltd. | 2018-02-12 |